NCT04828343View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 22, 2021

Primary Completion Date

April 11, 2022

Study Completion Date

April 11, 2022

Conditions
Healthy Study Participants
Interventions
DRUG

rozanolixizumab

Study participants will receive a single dose rozanolixizumab subcutaneously administered by manual push or a syringe driver.

OTHER

Placebo

Study participants will receive a single dose placebo subcutaneously administered by manual push or a syringe driver.

Trial Locations (1)

Unknown

Up0106 001, London

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY